Soon after [1 1-3H]retinoic acid (RA) (1.1 x 108 d.p.m.) was administered orally to rats either as a large dose (115 ,ug = 0.38 /tmol/rat) or mixed with unlabelled RA as a huge dose (22 mg = 73.33 ,umol/rat), retinoyl ,-glucuronide (RAG) was identified and characterized as a significant metabolite in the serum and small intestine. Of the administered dose, 70 % remained unchanged as retinoic acid in the stomach up to 1 h. Significant amounts of 5,6-epoxyretinoic acid, 4-hydroxyretinoic acid, esters of retinoic acid and several polar retinoids, including 4-oxoretinoic acid, were also detected in the stomach. No significant difference was observed in the nature of the retinoids found after a large or a huge dose; however, the ratio of RAG/RA was higher after a huge dose than after a large dose. Thus RAG, which is biologically active in vivo and in vitro, is formed quickly in significant amounts in tissues after a dose of RA.
INTRODUCTION
Retinoic acid (RA) is an important physiological metabolite of retinol in the control of epithelial-cell growth and cellular differentiation (Roberts & Sporn, 1984) . Both vitamin A deficiency and large doses of RA markedly affect embryonic development (Kochhar, 1967; Maden & Summerbell, 1986; Gunning et al., 1989) . Both physiological and toxic effects may be mediated at the gene level, at least in part, by nuclear retinoic acid receptors (Petkovich et al., 1987; Giguere et al., 1987) .
Metabolites of all-trans-RA in vivo include retinoyl ,3-glucuronide (RAG), 5,6-epoxyretinoic acid (5,6-ERA), 4-hydroxyretinoic acid (4-HRA) and 4-oxoretinoic acid (4-ORA) (Dunagin et al., 1966; McCormick et al., 1980; Napoli & McCormick, 1981; Zile et al., 1980 Zile et al., , 1982 Swanson et al., 1981; Silva & DeLuca, 1982) . 4-Oxo-13-cis-RA, its glucuronide, and other oxidized metabolites appear in the blood or bile after an oral dose of 13-cis-RA (Vane & Bugge, 1981; Vane et al., 1990) . In the studies cited above, RA usually was given by intravenous or intraperitoneal injection. However, in many of these past investigations, RAG would not have been extracted by the procedures used.
We recently synthesized RAG from RA chemically (Barua & Olson, 1985a ,b, 1989a and, thereafter, demonstrated the endogenous occurrence of RAG in human blood (Barua & Olson, 1986) .
The purpose of the present study, therefore, was to examine the metabolites of orally administered doses (both large and huge) of all-trans-RA in rats, with particular attention to the formation of RAG and its circulation in the blood. A preliminary communication concerning this study has previously appeared .
MATERIALS AND METHODS

Chemicals and solvents
All-trans-[1 1-3H]RA was obtained from SRI International, Menlo Park, CA, U.S.A., through the courtesy of the National Cancer Institute, Bethesda, MD, U.S.A. Other chemicals and solvents used and their purveyors were: all-trans-RA and ,8-glucuronidase from Escherichia coli (activity 570000 units/g) (Sigma Chemical Co., St. Louis, MO, U.S.A.); NaHCO3, acetone, methanol, dichloromethane, diethyl ether, ethyl acetate and hexane (Fisher Scientific Co., Fair Lawn, NJ, U.S.A.); silica gel for dry column chromatography (Woelm Pharma, Eschewege, Germany, and supplied through Universal Scientific, Atlanta, GA, U.S.A.); glucuronic acid and p-chloroperoxybenzoic acid (Aldrich Chemical Co., Milwaukee, WI, U.S.A.).
[1 1-3H]RA (2,Ci) was mixed with unlabelled RA (3 mg) and purified first by column chromatography on a small column of silica gel that was wet-packed with dichloromethane. All-trans-RA, which separated from traces of more-and less-polar compounds as a single major yellow band, was eluted with dichloromethane/diethyl ether (1:1, v/v). The all-trans-[l1-3H]-RA thus obtained, when analysed by isocratic reversed-phase h.p.l.c. as described below, was found to be > 99 % pure. The specific radioactivity was found to be 9.3 x 105 d.p.m./,ug. 5,6-ERA was prepared by treating methyl retinoate (2 mg) dissolved in diethyl ether (1 ml) with a solution of p-chloroperoxybenzoic acid (1 mg) in diethyl ether (1 ml). The crude methyl 5,6-epoxyretinoate was hydrolysed with methanolic NaOH [100% (w/v); 100,l]. After acidification with acetic acid, the retinoids were extracted, then purified by isocratic reversedphase h.p.l.c. 5,6-ERA [retention time (tR) 4 min] separated as the major band from another earlier unidentified band (tR 2 min) and showed a Amax of 321 nm that shifted to 337 nm when a drop of acetic acid was added to the h.p.l.c. solvent. The purified acidic form of 5,6-ERA showed a Amax. of 337 nm, which shifted to 308 nm, characteristic of the 5,8-furanoid structure, upon addition of a drop of dilute HC1. ORA and 4-hydroxyretinoic HRA were prepared as described previously (Barua & Ghosh, 1972 Sprague-Dawley rats weighing about 300 g were fed on a normal rat diet. Large doses of the retinoid were given to male rats and huge doses on day 10 of gestation to female pregnant rats, which were concomitantly used for study of teratogenicity. The rats were dosed by means of a Microman positive-displacement pipette (Gilson Medical Electronics, Villiers-le-Bel, France; supplied by Rainin Instruments Co., Woburn, MA, U.S.A.). The volumes of large and huge doses (containing the same amount of radioactivity) were 100,1 and 500,l respectively, which were pipetted well down into the throats of the animals. Another 50-100 #1 of peanut oil were pipetted subsequently into the mouth to rinse the dose down. The rats were anaesthetized with diethyl ether 0.5 or 1 h after the dose, the chest was cut open, and blood was collected from the heart by means of a syringe. Liver, stomach, small intestine, large intestine and kidneys were collected and kept frozen at -72°C until analysis. Blood was allowed to clot for about 15 min and then was centrifuged for 20 min at 1500 rev./min (500 g). Serum was separated and, whenever possible, analysed on the same day; otherwise, it was kept frozen at -72 'C.
Extraction of retinoids Serum (0.5 ml) and about 1 g portions of liver, kidney, small intestine and stomach (together with its contents) were extracted with a mixture of dichloromethane, ethyl acetate and methanol as described previously (Barua & Olson, 1989a) . The extracts were dissolved in methanol/dichloromethane [3: 1 (v/v); 100-500 ,ul], and portions (50-100 ,u) were analysed by h.p.l.c.
Control experiments
To determine whether the retinoids formed were artefacts of the extraction and isolation procedure, control experiments were conducted by using residual tissues after complete extraction of radioactivity. Thus [3H]RA solution (103d.p.m.) in methanol was added to residual liver and intestinal tissues that had been mixed previously with five times their weight of anhydrous Na2SO4. The mixture was ground, and the retinoids were extracted exactly the same way as described under 'Extraction of retinoids' above. The extract was then analysed by h.p.l.c.
Other procedures
Action of aIglucuronidase. ul) , or its extract, and other tissue extracts in 50,1u of methanol were diluted with phosphate-buffered saline (0.15 M-sodium phosphate/ 0.15 M-NaCl, pH 7.5; 0.5 ml) and incubated with ,i-glucuronidase (5 mg) at 37°C for 1 h. Retinoids were extracted and analysed as described under 'Extraction of retinoids' above.
Determination of radioactivity. Portions (Table 2) , radioactive 5,6-ERA, 4-HRA and 4-ORA were also detected and characterized. Two other non-polar radioactive compounds, one tentatively characterized as an ester of RA, were also present (Table 2) . However, no RAG was detected in the stomach.
Serum. Although [3H]RA was found to circulate in the blood within 30 min of dosing (Table 3) , the predominant radioactive peak found at that time was a polar compound that was eluted close to the solvent front during h.p.l.c. Although the identity of this compound was not established with certainty, 4-ORA exhibits similar h.p.l.c. behaviour. At 1 h after a large or huge dose, however, RA was a predominant compound detected in the blood. Small quantities of 4-HRA and 5,6-ERA (Table 3) were also identified in the blood. Retinoyl fl-glucuronide (RAG) was found to be the major metabolite (15.2 nmol/ml) (Table 3; Fig.  la ) 1 h after a huge dose of RA and a significant metabolite (6 nmol of RAG/ml) in the serum 30 min after a large dose. Non-polar radioactive compounds (tR 18-28 min: Fig. lc) , possibly esters of RA, were found in the serum 1 h after either dose of RA.
Small intestine. Irrespective of the size of the dose, [3H]RA was the major compound in the small intestine (Table 3) . Among all the tissues, however, the highest concentration of RAG was found in the small intestine (Table 3 ). Smaller quantities of 5,6-ERA, 4-HRA, 4-ORA mixed with polar compounds, and a nonpolar compound, presumably an ester of RA, were also present in the small intestine (Table 3) .
Liver. The pattern of radioactive compounds found in the liver after a large or huge dose was similar (Table 3) . At both 30 min and 1 h, RA predominated, followed by a polar fraction, which probably included 4-ORA. A significant amount of 5,6-ERA and a small quantity of RAG were also detected.
Kidney. After a 0.38 umol dose, kidney radioactivity was low (0.1 %o) at 30 min, but was much higher (2.5 %,) after 1 h (Table  1) . At both doses, administered RA was the major radioactive compound present at 30 min or 1 h after the dose (Table 3) .
Metabolism of all-trans-[l 1-3H]retinoic acid in rats Small quantities of 4-ORA, 5,6-ERA, and 4-HRA were also detected in the kidney. However, RAG was not found in the kidneys within 1 h of dosing (Table 3) .
Characterization of metabolites in blood and other tissues
Retinoyl /I-glucuronide. The tR of radiolabelled RAG in blood and other tissues was identical with that of standard RAG in at least two different h.p.l.c. procedures. The tR values for RAG and RA in the gradient h.p.l.c. system were 9.8 and 11.8 min respectively. In certain serum or tissue extracts where RAG was present as a minor metabolite, especially after a large dose, RAG appeared as a shoulder on the RA peak in the gradient h.p.l.c. procedure. To confirm that the peak was indeed due to RAG, and not due to cis-RA, isocratic h.p.l.c. using methanol/water (7:3, v/v) at a flow rate of 1.2 ml/min was used. Under these conditions, RAG (tR 7 min) separated very well from both cis-RA (tR 13.5 min) and trans-RA (tR 16 min) (Figs. 2a and 2b) .
The u.v.-absorption spectrum of RAG, obtained from serum as a metabolite after a huge dose of RA, was identical with that of standard RAG (AmaX. at 360 nm in h.p.l.c. solvent) (Fig. 2c) .
The identity of RAG, obtained after a large or huge dose, was further confirmed by treating the serum, its extract or tissue extracts, with ,J-glucuronidase. After treatment, both the RAG peak in the h.p.l.c. profile (Fig. lb) and the radioactivity associated with it ( Fig. lc) disappeared, and the area of the RA peak and the radioactivity associated with it correspondingly increased (Figs. lb and 1c) .
5,6-ERA, 4-HRA and 4-ORA. The identity of these metabolites was established from their retention time in both isocratic and gradient h.p.l.c. procedures and by examination of spectra of fractions collected after a huge dose. The ionic form of 5,6-ERA, both in the standard and from an extract of the stomach and its contents, exhibited Amax. at 321 nm in the h.p.l.c. solvent (Fig.   2d ). The maximum shifted to 308 nm in the presence of a trace of HCI, owing to rearrangement of the 5,6-epoxide form to the 5,8-furanoid form or to 337 nm in the presence of acetic acid, due to neutralization of the charge (Fig. 2d) . Both standard 4-HRA and a retinoid isolated from stomach and its contents showed Amax. at 340 nm in the h.p.l.c. solvent mixture (Fig. 2e) . Similarly, both standard 4-ORA and a derivative of RA isolated from stomach and its contents exhibited AmaX. at 355 nm (Fig. 2e) . Because of the co-elution of ORA with unidentified compounds that absorb strongly at shorter wavelengths, the small peak at 280 nm, characteristic of the 4-oxo group, was masked. Thus the exact concentration of 4-ORA could not be determined. (Olson, 1968; Zile et al., 1980) and small intestine of the rat (Zile et al., 1982) . Recently, after a 80 mg dose of 13-cis-RA, the presence of small amounts of the glucuronide conjugate of 1 3-cis-RA along with other oxidized and glucuronidated metabolites in human bile has been reported (Vane et al., 1990) . With the availability of synthetic RAG (Barua & Olson, 1985a , 1989a (Nath & Olson, 1967) was confirmed (Barua & Olson, 1985a) . RAG, like RA, induces the differentiation of HL-60 cells, but is less cytotoxic (Gallup et al., 1987; Zile et al., 1987; Janick-Buckner et al., 1991) and less teratogenic (Gunning et al., 1989 than RA. The occurrence of RAG in human blood as an endogenous compound has been clearly demonstrated (Barua & Olson, 1986) , but the appearance of RAG in the blood after administration of RA has not previously been reported.
In the present study we have been able to show that RAG is synthesized rapidly from administered RA and can be detected in the blood within 30 min after the administration of RA. The ratio of RAG/RA in the serum was much higher after a huge dose (1.10) of RA than after a large dose (0.25). After a large dose of RA, the RAG peak was best resolved from RA and other metabolites by isocratic h.p.l.c.
The highest concentration of RAG was found in the small intestine (Table 3) . In this regard, Zile et al. (1982) earlier found that the small intestine was a major site for the biosynthesis of RAG from RA. Although we demonstrated previously that RAG was the major retinoid in the liver up to 24 h after an intraperitoneal dose of [3H]RAG (Barua & Olson, 1989a) , only very small amounts were found after oral dosing with RA (Table  3 ). In the present study, we could not detect any RAG in the kidney within 1 h after the dose of RA.
After the oral administration of a large dose of RA, radioactivity recovered from the blood and the major tissues (e.g. liver, small intestine and kidney) accounted for only 3.5-9.9 % of the total dose (Table 1) . To locate the rest of the administered radioactivity, the stomach and its contents were extracted and analysed. Indeed, 64-70% of the administered radioactivity, which equalled 88-95 % of the total recovered radioactivity, was still present in the stomach 0.5-1 h after the dose. H.p.l.c. analysis of the extract from the stomach and its contents showed that, besides administered RA, three other radioactive compounds (namely 4-ORA, 4-HRA and 5,6-ERA) were present in amounts sufficient for characterization by their u.v. spectra. Furthermore, 5,6-ERA was characterized by demonstrating the expected shifts in its absorption maximum in the presence of acetic acid and HCI. Thus the 5,6-epoxy ring clearly does not isomerize to the furanoid form in the presence of stomach acid.
5,6-ERA was previously characterized as a physiological metabolite of RA (McCormick et al., 1980 (McCormick et al., , 1982 McCormick & Napoli, 1982; DeLuca et al., 1981; Leo et al., 1984) on the basis of its molecular ion (MI), which is the same for both the 5,6-and the 5,8-epoxide of RA. In our studies, the small intestine and its contents also contained lesser amounts of 5,6-ERA. Whether 5,6-ERA, 4-ORA and 4-HRA found in the intestine and other tissues originated primarily in situ or were derived in part from those formed in the stomach merits further study.
As far as we are aware, this is the first study where the stomach and its contents have been analysed after a dose of RA. It seems unlikely that 5,6-RA, 4-ORA, 4-HRA and some non-polar esters are produced metabolically in stomach cells. Moreover, because a total of < 1 % of oxidized derivatives of RA were formed in our inactivated-control experiments, it seems unlikely that their formation can be attributed to an artefact of the process of extraction and analysis. Thus the most plausible explanation is that they are formed in the stomach by a process of chemical oxidation. Because RA is only a very minor component of foods, whether ingested retinyl ester, the major dietary form of vitamin A, is affected similarly merits attention.
